Literature DB >> 25344291

Common genetic variants on 3q28 contribute to non-small cell lung cancer susceptibility: evidence from 10 case-control studies.

Yu-xing Jin1, Ge-ning Jiang, Hui Zheng, Liang Duan, Jia-an Ding.   

Abstract

The association between common variations (rs10937405, rs4488809) on 3q28 and lung cancer has been widely evaluated in various ethnic groups, since it was first identified through genome-wide association approach. However, the results have been inconclusive. To derive a more precise estimation of the relationship and the effect of factors that might modify the risk, we performed this meta-analysis. The random-effects model was applied, addressing heterogeneity and publication bias. A total of 10 articles involving 36,221 cases and 58,108 controls were included. Overall, the summary per-allele OR of 1.19 (95 % CI 1.14-1.25, P < 10(-5)) and 1.17 (95 % CI 1.10-1.23, P < 10(-5)) was found for the rs10937405 and rs4488809 polymorphisms, respectively. Significant results were also observed in heterozygous and homozygous when compared with wild genotype for these polymorphisms. Significant results were found in East Asians when stratified by ethnicity, whereas no significant associations were found among Caucasians. After stratifying by sample size, study design, control source and sex, significant associations were also obtained. In addition, our data indicate that these polymorphisms are involved in lung cancer susceptibility and confer its effect primarily in lung adenocarcinoma when stratified by histological subtype. Furthermore, significant associations were also detected both never-smokers and smokers for these polymorphisms. In conclusion, this meta-analysis demonstrated that rs10937405 and rs4488809 are a risk factor associated with increased non-small cell lung cancer susceptibility, particularly for East Asian populations.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25344291     DOI: 10.1007/s00438-014-0934-1

Source DB:  PubMed          Journal:  Mol Genet Genomics        ISSN: 1617-4623            Impact factor:   3.291


  53 in total

1.  Variation in TP63 is associated with lung adenocarcinoma susceptibility in Japanese and Korean populations.

Authors:  Daiki Miki; Michiaki Kubo; Atsushi Takahashi; Kyong-Ah Yoon; Jeongseon Kim; Geon Kook Lee; Jae Ill Zo; Jin Soo Lee; Naoya Hosono; Takashi Morizono; Tatsuhiko Tsunoda; Naoyuki Kamatani; Kazuaki Chayama; Takashi Takahashi; Johji Inazawa; Yusuke Nakamura; Yataro Daigo
Journal:  Nat Genet       Date:  2010-09-26       Impact factor: 38.330

2.  Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1.

Authors:  Christopher I Amos; Xifeng Wu; Peter Broderick; Ivan P Gorlov; Jian Gu; Timothy Eisen; Qiong Dong; Qing Zhang; Xiangjun Gu; Jayaram Vijayakrishnan; Kate Sullivan; Athena Matakidou; Yufei Wang; Gordon Mills; Kimberly Doheny; Ya-Yu Tsai; Wei Vivien Chen; Sanjay Shete; Margaret R Spitz; Richard S Houlston
Journal:  Nat Genet       Date:  2008-04-02       Impact factor: 38.330

Review 3.  The roles of p63 in cancer.

Authors:  Elsa R Flores
Journal:  Cell Cycle       Date:  2007-02-03       Impact factor: 4.534

Review 4.  Contribution of p53, p63, and p73 to the developmental diseases and cancer.

Authors:  K Tomkova; M Tomka; V Zajac
Journal:  Neoplasma       Date:  2008       Impact factor: 2.575

5.  Properties of the six isoforms of p63: p53-like regulation in response to genotoxic stress and cross talk with DeltaNp73.

Authors:  A Petitjean; C Ruptier; V Tribollet; A Hautefeuille; F Chardon; C Cavard; A Puisieux; P Hainaut; C Caron de Fromentel
Journal:  Carcinogenesis       Date:  2007-11-28       Impact factor: 4.944

Review 6.  p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53.

Authors:  G Melino
Journal:  Cell Death Differ       Date:  2011-07-15       Impact factor: 15.828

7.  Common 5p15.33 and 6p21.33 variants influence lung cancer risk.

Authors:  Yufei Wang; Peter Broderick; Emily Webb; Xifeng Wu; Jayaram Vijayakrishnan; Athena Matakidou; Mobshra Qureshi; Qiong Dong; Xiangjun Gu; Wei Vivien Chen; Margaret R Spitz; Timothy Eisen; Christopher I Amos; Richard S Houlston
Journal:  Nat Genet       Date:  2008-11-02       Impact factor: 38.330

Review 8.  A comprehensive review of genetic association studies.

Authors:  Joel N Hirschhorn; Kirk Lohmueller; Edward Byrne; Kurt Hirschhorn
Journal:  Genet Med       Date:  2002 Mar-Apr       Impact factor: 8.822

9.  The PstI/RsaI and DraI polymorphisms of CYP2E1 and head and neck cancer risk: a meta-analysis based on 21 case-control studies.

Authors:  Kefu Tang; Yang Li; Zhao Zhang; Yunmin Gu; Yuyu Xiong; Guoyin Feng; Lin He; Shengying Qin
Journal:  BMC Cancer       Date:  2010-10-22       Impact factor: 4.430

10.  Five glutathione s-transferase gene variants in 23,452 cases of lung cancer and 30,397 controls: meta-analysis of 130 studies.

Authors:  Zheng Ye; Honglin Song; Julian P T Higgins; Paul Pharoah; John Danesh
Journal:  PLoS Med       Date:  2006-03-07       Impact factor: 11.069

View more
  3 in total

1.  Non-small-cell lung cancer pathological subtype-related gene selection and bioinformatics analysis based on gene expression profiles.

Authors:  Jiangpeng Chen; Xiaoqi Dong; Xun Lei; Yinyin Xia; Qing Zeng; Ping Que; Xiaoyan Wen; Shan Hu; Bin Peng
Journal:  Mol Clin Oncol       Date:  2017-11-27

2.  Quantitative assessment of common genetic variations in HLA-DP with hepatitis B virus infection, clearance and hepatocellular carcinoma development.

Authors:  Lei Yu; Yi-ju Cheng; Ming-liang Cheng; Yu-mei Yao; Quan Zhang; Xue-ke Zhao; Hua-juan Liu; Ya-xin Hu; Mao Mu; Bi Wang; Guo-zhen Yang; Li-li Zhu; Shuai Zhang
Journal:  Sci Rep       Date:  2015-10-14       Impact factor: 4.379

3.  A Functional Polymorphism in Accessible Chromatin Region Confers Risk of Non-Small Cell Lung Cancer in Chinese Population.

Authors:  Jieyi Long; Tingting Long; Ying Li; Peihong Yuan; Ke Liu; Jiaoyuan Li; Liming Cheng
Journal:  Front Oncol       Date:  2021-09-06       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.